Evaluating the Rationality of the International Guideline's Recommendations Regarding Selective Coverage of Level Ib in Node Clinical Target Volume With Nasopharyngeal Carcinoma: Results From a Real-World Series

医学 鼻咽癌 指南 鼻腔 放射治疗 入射(几何) 内科学 肿瘤科 放射科 外科 病理 光学 物理
作者
Qiaojuan Guo,Nan Xiao,Hua-shan Xu,Jingfeng Zong,Youping Xiao,Tianzhu Lu,Yun Xu,Bing Chen,Chanchan Hu,Xuru Zhang,Jianji Pan,Shu-I Lin
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier]
卷期号:111 (3): e383-e384
标识
DOI:10.1016/j.ijrobp.2021.07.1123
摘要

Purpose/Objective(s)Although the International Guideline for the delineation of clinical target volume (CTV) in nasopharyngeal carcinoma (NPC) patients has provided practical reference for the elective coverage of level 1b, there are marked variations in practice among different institutions, and the rationality of the recommendations remained proven. The purpose of this study was to evaluate its rationality in real-world data and provide clinical evidence for the refinement of nodal CTV delineation in nasopharyngeal carcinoma (NPC).Materials/MethodsPatients with histologically-proven NPC who received definitive Intensity-modulated radiation therapy (IMRT) with or without chemotherapy at Dr. SJ Lin's attending group in our institution between June 2005 and December 2012 were candidates for this retrospectively study. Other main eligible criteria including the following five situations: 1) level Ib metastasis;2)involvement of the submandibular gland;3) involvement of structures that drain to level Ib as the first echelon site (the oral cavity, anterior half of nasal cavity involvement);4) involvement of level II LNs with extracapsular extension (ECE); 5) level II nodal involvement with maximum nodal axial diameter (MAD) greater than 2 cm. Survival outcomes focused on regional recurrence-free survival (RRFS) and incidence rate of Ib recurrence were analyzed.ResultsA total of 451 patients were finally included according to the above criteria. There were 27, 37, 6, 12, 285 and 414 cases be classified as level Ib metastasis, submandibular gland involvement, oral cavity involvement, anterior half of nasal cavity involvement, level II LNs involvement with ECE and level II nodal involvement with MAD greater than 2 cm, respectively. Among these 451 patients, 60 patients received level Ib-covering IMRT due to the first three principles of the International Guideline according to our attending group's protocol. Of note, patients who had Ib involvement would receive ultrasound guided puncture, only those who had positive pathological results would undergo Ib-covering IMRT in our attending group. For the remaining 391 patients who only fulfilled the last two criteria and/or Ib involvement with negative pathological results, they all received level Ib-sparing IMRT, reported 6-year RRFS was 94.3%. For the 22 patients who had regional recurrence at censorship, only 3 (3/391, 0.78%) were recorded as Ib recurrence.ConclusionLevel Ib-sparing IMRT should be safe and feasible for patients who only had involvement of level II LNs with ECE, and/or had a MAD of greater than 2 cm in level II LNs, and/or Ib involvement with negative pathological results. Further well-designed multi-center prospective trials should be conducted to confirm our results. Although the International Guideline for the delineation of clinical target volume (CTV) in nasopharyngeal carcinoma (NPC) patients has provided practical reference for the elective coverage of level 1b, there are marked variations in practice among different institutions, and the rationality of the recommendations remained proven. The purpose of this study was to evaluate its rationality in real-world data and provide clinical evidence for the refinement of nodal CTV delineation in nasopharyngeal carcinoma (NPC). Patients with histologically-proven NPC who received definitive Intensity-modulated radiation therapy (IMRT) with or without chemotherapy at Dr. SJ Lin's attending group in our institution between June 2005 and December 2012 were candidates for this retrospectively study. Other main eligible criteria including the following five situations: 1) level Ib metastasis;2)involvement of the submandibular gland;3) involvement of structures that drain to level Ib as the first echelon site (the oral cavity, anterior half of nasal cavity involvement);4) involvement of level II LNs with extracapsular extension (ECE); 5) level II nodal involvement with maximum nodal axial diameter (MAD) greater than 2 cm. Survival outcomes focused on regional recurrence-free survival (RRFS) and incidence rate of Ib recurrence were analyzed. A total of 451 patients were finally included according to the above criteria. There were 27, 37, 6, 12, 285 and 414 cases be classified as level Ib metastasis, submandibular gland involvement, oral cavity involvement, anterior half of nasal cavity involvement, level II LNs involvement with ECE and level II nodal involvement with MAD greater than 2 cm, respectively. Among these 451 patients, 60 patients received level Ib-covering IMRT due to the first three principles of the International Guideline according to our attending group's protocol. Of note, patients who had Ib involvement would receive ultrasound guided puncture, only those who had positive pathological results would undergo Ib-covering IMRT in our attending group. For the remaining 391 patients who only fulfilled the last two criteria and/or Ib involvement with negative pathological results, they all received level Ib-sparing IMRT, reported 6-year RRFS was 94.3%. For the 22 patients who had regional recurrence at censorship, only 3 (3/391, 0.78%) were recorded as Ib recurrence. Level Ib-sparing IMRT should be safe and feasible for patients who only had involvement of level II LNs with ECE, and/or had a MAD of greater than 2 cm in level II LNs, and/or Ib involvement with negative pathological results. Further well-designed multi-center prospective trials should be conducted to confirm our results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无足鸟应助滴滴哒哒采纳,获得10
刚刚
胡图图完成签到,获得积分10
2秒前
大豆11s发布了新的文献求助10
3秒前
3秒前
希望天下0贩的0应助lili采纳,获得10
5秒前
小龙关注了科研通微信公众号
5秒前
大白狐狸完成签到,获得积分10
5秒前
6秒前
我是老大应助sss采纳,获得10
6秒前
张小星完成签到,获得积分20
7秒前
CodeCraft应助大馒头采纳,获得10
8秒前
知犯何逆发布了新的文献求助10
10秒前
11秒前
garrick完成签到,获得积分10
12秒前
12秒前
蛋泥关注了科研通微信公众号
12秒前
英姑应助dandan采纳,获得10
14秒前
14秒前
张张发布了新的文献求助30
16秒前
16秒前
17秒前
17秒前
17秒前
18秒前
18秒前
18秒前
lili发布了新的文献求助10
19秒前
19秒前
20秒前
orixero应助hhh采纳,获得10
20秒前
20秒前
23秒前
bridge发布了新的文献求助10
23秒前
滴滴哒哒发布了新的文献求助20
23秒前
lxz发布了新的文献求助10
23秒前
自信筮发布了新的文献求助10
24秒前
Seven发布了新的文献求助10
24秒前
WANG发布了新的文献求助10
24秒前
25秒前
让我毕业吧完成签到,获得积分20
27秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
《粉体与多孔固体材料的吸附原理、方法及应用》(需要中文翻译版,化学工业出版社,陈建,周力,王奋英等译) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3084626
求助须知:如何正确求助?哪些是违规求助? 2737675
关于积分的说明 7546358
捐赠科研通 2387296
什么是DOI,文献DOI怎么找? 1265911
科研通“疑难数据库(出版商)”最低求助积分说明 613207
版权声明 598409